<DOC>
	<DOCNO>NCT00002920</DOCNO>
	<brief_summary>RATIONALE : It yet know whether medroxyprogesterone effective prevent endometrial disorder patient breast cancer take tamoxifen . PURPOSE : Randomized phase III trial study effectiveness medroxyprogesterone prevent endometrial disorder postmenopausal woman ductal carcinoma situ , lobular carcinoma situ , Paget 's disease nipple , stage I breast cancer , stage II breast cancer take tamoxifen .</brief_summary>
	<brief_title>S9630 , Medroxyprogesterone Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare endometrial pathologic diagnosis ( proliferative change , simple cystic hyperplasia , complex adenomatous hyperplasia , hyperplasia atypia , carcinoma ) postmenopausal woman breast carcinoma treat adjuvant tamoxifen randomly assign medroxyprogesterone acetate ( MA ) v observation . - Compare endometrial pathologic diagnosis ( persistent endometrial hyperplasia , atypia , carcinoma ) result tamoxifen discontinuation intermittent bleed patient treat regimen . - Characterize incidence spontaneous regression progression simple cystic hyperplasia patient . - Characterize endometrial biopsy result use different endometrial stripe width cut-off point , case width least 5 mm endovaginal ultrasound patient receive tamoxifen . - Compare change time endometrial oncogene expression ( e.g. , c-fos , c-jun , p53 , IGF1 ) receptor status patient receive tamoxifen without prior chemotherapy randomly assign MA vs observation . - Describe association among change gene expression , receptor status , endometrial abnormality , length tamoxifen exposure , prior chemotherapy patient . OUTLINE : This randomize , multicenter study . Patients stratify accord adjuvant chemotherapy ( yes v ) , number positive node ( 0-3 v least 4 ) , endovaginal sonogram endometrial stripe ( le 5 mm v least 5 mm ) . Patients randomize 1 2 arm . All patient receive adjuvant oral tamoxifen daily five year . - Arm I : Patients undergo observation . - Arm II : Patients receive oral medroxyprogesterone acetate day 1-14 . Treatment repeat every 3 month 5 year . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 330 patient ( 165 per arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically proven diagnosis : Primary invasive adenocarcinoma unilateral bilateral breast Stage I , IIA , IIB ( T13 , N01 , M0 ) No recurrent invasive breast cancer Ductal carcinoma situ ( DCIS ) Lobular carcinoma situ ( LCIS ) microinvasion Paget 's disease nipple No sarcoma , lymphoma , apocrine , adenocystic , squamous cell cancer breast Currently free breast cancer ( evidence disease ) No evidence distant disease chest xray chest CT scan mammogram opposite breast within past year Prior definitive local treatment primary lesion ( mastectomy breastsparing procedure radiotherapy ) either axillary node sentinel node biopsy Surgical margin clear infiltrate carcinoma ( type ) DCIS No gross microscopically positive margin except : Invasive cancer DCIS focal margin treat definitive radiotherapy Gross LCIS final margin Biopsy requirement waive DCIS LCIS minimal microinvasion Patients breastsparing procedure must receive plan receive radiotherapy start tamoxifen treatment No endometrial simple cystic hyperplasia , proliferative change , complex ( adenomatous ) atypical hyperplasia , carcinoma Patients must plan one following : Starting adjuvant tamoxifen five year OR Started tamoxifen within 28 day prior study plan receive adjuvant tamoxifen five year Hormone receptor status : Candidate adjuvant tamoxifen therapy PATIENT CHARACTERISTICS : Age : Adult Sex : Female Menopausal status : Postmenopausal define : At least 1 year since last menstrual period At least 2 month since bilateral oophorectomy prior breast cancer diagnosis 412 month since last menstrual period FSH elevate postmenopausal range Postmenopausal estrogen therapy 55 year age old Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Fertile patient must use effective contraception least 2 month study No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , stage I II cancer currently complete remission No concurrent nonmalignantrelated illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Adjuvant chemotherapy allow No concurrent chemotherapy Endocrine therapy : See Disease Characteristics No prior hormonal treatment breast cancer ( except tamoxifen ) No concurrent postmenopausal estrogen therapy Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics No prior concurrent hysterectomy Other : No prior current participation adjuvant intergroup trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>endometrial cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>lobular breast carcinoma situ</keyword>
	<keyword>Paget disease breast</keyword>
</DOC>